Float Short %

13.77

Margin Of Safety %

Put/Call OI Ratio

0.14

EPS Next Q Diff

EPS Last/This Y

0.37

EPS This/Next Y

0.13

Price

1.54

Target Price

5.4

Analyst Recom

Performance Q

-50.8

Relative Volume

0.52

Beta

0.36

Ticker: AKBA

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	AKBA	1.66	0.15	0.14	49037
2025-11-11	AKBA	1.8	0.15	0.03	50625
2025-11-12	AKBA	1.85	0.14	0.07	51304
2025-11-13	AKBA	1.755	0.13	0.00	53735
2025-11-14	AKBA	1.67	0.13	0.19	53650
2025-11-17	AKBA	1.77	0.12	0.00	54420
2025-11-18	AKBA	1.65	0.12	0.01	54737
2025-11-19	AKBA	1.595	0.13	0.18	52121
2025-11-20	AKBA	1.535	0.13	0.21	52535
2025-11-21	AKBA	1.54	0.13	0.15	52730
2025-11-24	AKBA	1.6	0.14	0.04	44208
2025-11-25	AKBA	1.565	0.14	0.04	45183
2025-11-26	AKBA	1.59	0.14	0.07	45377
2025-12-01	AKBA	1.5	0.14	0.01	45943
2025-12-02	AKBA	1.475	0.14	0.47	46058
2025-12-03	AKBA	1.57	0.14	0.15	46669
2025-12-04	AKBA	1.595	0.14	0.25	46833
2025-12-05	AKBA	1.535	0.14	0.17	46894
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	AKBA	1.67	80.0	-	-0.02
2025-11-11	AKBA	1.81	80.0	-	-0.02
2025-11-12	AKBA	1.85	80.0	-	-0.02
2025-11-13	AKBA	1.75	80.0	-	-0.02
2025-11-14	AKBA	1.67	80.0	-	-0.02
2025-11-17	AKBA	1.76	110.0	-	-0.02
2025-11-18	AKBA	1.65	110.0	-	-0.02
2025-11-19	AKBA	1.59	110.0	-	-0.02
2025-11-20	AKBA	1.53	110.0	-	-0.02
2025-11-21	AKBA	1.54	110.0	-	-0.02
2025-11-24	AKBA	1.60	110.0	-	-0.02
2025-11-25	AKBA	1.57	110.0	-	0.04
2025-11-26	AKBA	1.59	110.0	-	0.04
2025-12-01	AKBA	1.51	115.0	-	0.04
2025-12-02	AKBA	1.47	115.0	-	0.04
2025-12-03	AKBA	1.57	115.0	-	0.04
2025-12-04	AKBA	1.60	115.0	-	0.04
2025-12-05	AKBA	1.54	115.0	-	0.04
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	AKBA	-0.81	5.19	11.43
2025-11-11	AKBA	-0.81	5.19	11.43
2025-11-12	AKBA	-0.81	5.19	13.84
2025-11-13	AKBA	-0.81	5.19	13.83
2025-11-14	AKBA	-0.81	5.19	13.83
2025-11-17	AKBA	-0.81	6.13	13.83
2025-11-18	AKBA	-0.80	6.13	13.83
2025-11-19	AKBA	-0.80	6.13	13.83
2025-11-20	AKBA	-0.80	6.13	13.83
2025-11-21	AKBA	-0.80	6.13	13.83
2025-11-24	AKBA	-0.80	6.73	13.83
2025-11-25	AKBA	-0.80	6.73	13.83
2025-11-26	AKBA	-0.80	6.73	13.77
2025-12-01	AKBA	-0.80	6.64	13.77
2025-12-02	AKBA	-0.80	6.64	13.77
2025-12-03	AKBA	-0.80	6.64	13.77
2025-12-04	AKBA	-0.80	6.64	13.77
2025-12-05	AKBA	-0.80	6.64	13.77
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.01

Avg. EPS Est. Next Quarter

0.01

Insider Transactions

-0.8

Institutional Transactions

6.64

Beta

0.36

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

2.11

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-95.1

Target Price

5.4

P/E

Forward P/E

12.62

PEG

P/S

1.82

P/B

9.82

P/Free Cash Flow

12.7

EPS

-0.08

Average EPS Est. Cur. Y

0.04

EPS Next Y. (Est.)

0.17

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-7.07

Relative Volume

0.52

Return on Equity vs Sector %

-65.2

Return on Equity vs Industry %

-45.6

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.07

EBIT Estimation

Akebia Therapeutics, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 181

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

stock quote shares AKBA – Akebia Therapeutics Inc. Stock Price stock today

news today AKBA – Akebia Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch AKBA – Akebia Therapeutics Inc. yahoo finance google finance

stock history AKBA – Akebia Therapeutics Inc. invest stock market

stock prices AKBA premarket after hours

ticker AKBA fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: AKBA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y